← All stocks

Phio Pharmaceuticals Corp.

PHIO Net buying
CIK 0001533040 #5173 in the set updated 17 Sep 2026
Bought (120 mo)
$212.87K
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$108.09K
$0.00 on a plan · $0.00 straight out of an exercise
Sold at will
$108.09K
4 of 4 sales
Net
+$104.78K
+$104.78K against sales at will

By person

17 insiders · 59 transactions
0.8×

Robert J. Bitterman holds only 0.8 times base salary in stock. $373.76K of shares against $419.05K in salary for 2025.

Salary from the company's own proxy. The shares are what Robert J. Bitterman last reported holding, valued at $1.03, the price Common Stock, $.0001 par value was last bought or sold at on the open market here, on 15 Sep 2026.

Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Eliseev Alexey
Chief Business Officer
$108.09K (4)
−$108.09K
950,312
$978.82K
+16.2%
Bitterman Robert J
Chairman, Pres. & CEO
$74.00K (21)
+$74.00K
362,871
$373.76K
CAUWENBERGH GEERT
Director
$58.08K (21)
+$58.08K
5,585
$5.75K
Dispersyn Gerrit
President & CEO
$29.52K (5)
+$29.52K
212,327
$218.70K
Ferrara Robert L
Director
$21.81K (6)
+$21.81K
38,666
$39.83K
Plott Ronald Todd
Director
$17.10K (1)
+$17.10K
15,000
$15.45K
BRADFORD PATRICIA A
Director
$12.36K (1)
+$12.36K
57,651
$59.38K
Barrett John A
Chief Development Officer
222,991
$229.68K
Carson Lisa Cabott
Chief Financial Officer
81,112
$83.55K
Deming David H
Director
37,800
$38.93K
Lockshin Curtis
Director
35,155
$36.21K
Freeman Jonathan E
Director
32,655
$33.63K
Dorman H. Paul
Director
20,370
$20.98K
Brownlie Keith L
Director
20,000
$20.60K
Pavco Pamela
Chief Development Officer
17,173
$17.69K
+183.3%
Infarinato Robert M.
VP, CFO
11,000
$11.33K
Kontulis Caitlin
Secretary & VP Finance & Admin
10,643
$10.96K

No percentages here. This company's share count has moved by a factor of 11.0 over the window, from 1,055,219 to 11,617,250 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

Nothing of that kind in this period.

What was left out

Form 4 filings counted 148
Amendments (4/A) skipped 1
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 0
Sales at will 4
Transactions with no price 0
Shares from compensation/vesting 4,213,373
Sales filed before the plan box existed 4
History held since 20 Dec 2016